X
Monday, June 9, 2025
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

New MHRA Regulation Revamps Lowest-Risk UK Clinical Trials

Content Team by Content Team
19th October 2023
in Clinical Trials, News

The Medicines and Healthcare products Regulatory Agency has gone on to launch a new scheme that seeks to lessen the nod time when it comes to clinical trials in the UK that are at lowest risk by more than 50%. 

The novel notification scheme is based on the one illustrated in the MHRA’s clinical trials consultation, which has received approval from 74% of the respondents.

This happens to be a significant component of the regulator’s overall revision of the clinical trials regulation that went on to be announced in March 2023. The goal of this revision is to position the UK as one of the best destinations when it comes to conducting clinical trials.

It is well to be noted that the eligibility criteria for clinical trials under the MHRA’s new Notification Scheme are as follows:

As per Andrea Manfrin, who happens to be the Deputy Director of Clinical Investigations and Trials at MHRA, the scheme allows for a more efficient and equal method of handling Clinical Trial Authorizations (CTAs) for the initial applications in Phase III as well as IV trials.

The fact is that the lowest-risk of these trials will be handled by the MHRA inside a span of 14 days, as opposed to the mandatory 30 days. The trial sponsor will need to show that the trial satisfies the MHRA’s criteria, which include safety issues associated with the investigational medicine.

The MHRA states that approximately 20% of initial clinical trial requests in the UK are predicted to meet the criteria for the Notification Scheme.

The new scheme adheres to specific criteria, and it is well worth noting that the amended applications for clinical trials will not be considered eligible. The agency stated that trials satisfying the eligibility criteria will continue to have to obtain a verdict from a research ethics committee.

Dr. June Raine, the Chief Executive of MHRA, stressed the importance of prioritising patients’ well-being. She suggested that clinical trial sponsors utilise the new scheme for all trials that meet the necessary criteria.

Manfrin expressed that the proposed scheme would go on to provide patients with quicker access to perhaps some life-saving medications. This would be achieved by expediting the licencing process, which would eventually help the pharmaceutical industry across the world. 

Manfrin said that one of the main challenges when creating the scheme was to establish an accurate method for measuring its success. In order to tackle these obstacles, the plan will be implemented in multiple phases to ensure an in-depth assessment, with a particular focus on the safety of the patients, which is an utmost priority, as well as the proposal’s scalability.

Advocating for the future of clinical trials in the UK

Dr. Janet Messer, who is the Director of Approvals at the Health Research Authority, mentioned that the combined review has already cut down the time required for examining clinical trials by a half as opposed to five years ago. She expressed interest in examining how the UK’s fast-track Research Ethics Service can work in tandem with the new notification scheme to further hurry up high-quality health and also social care research.

The MHRA has concluded that it will continue to review the criteria for notification of clinical trials and has declared that there is potential for the scheme to be broadened to include medium-risk clinical trials in the times to come.  

Previous Post

Alternative Tools For Facility Assessments Provided By FDA

Next Post

APAC Pandemic Readiness - A Workforce Training Efforts Goal

Related Posts

Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
Clinical Development
Articles

AI Revolutionizing Drug Discovery and Clinical Development

19th April 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Omics Based Clinical Trials
Asia

Asia Pacific Omics-Based Clinical Trials Market Growth

16th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Next Post

APAC Pandemic Readiness - A Workforce Training Efforts Goal

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Notifications